View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Bonduelle - Statement of availability of 2024-2025 Universal Registrat...

Bonduelle - Statement of availability of 2024-2025 Universal Registration Document BONDUELLE  Head office: "La Woestyne" - 59173 Renescure - FranceBonduelle a French S.C.A (Partnership limited by Shares) with a capital of 57 102 699,50 eurosRegistered under number : 447 250 044 ( Dunkerque Commercial and Companies Register) Villeneuve d’Ascq, October 17, 2025 Statement of availability of the 2024-2025 Universal Registration Document The Bonduelle Group announces that its 2024-2025 Universal Registration Document (document d’enregistrement universel) was filed with the Autorité des Mar...

 PRESS RELEASE

Bonduelle - Mise à disposition du document d'enregistrement universel ...

Bonduelle - Mise à disposition du document d'enregistrement universel 2024-2025 BONDUELLE Siège social - "La Woestyne" - 59173 Renescure - FranceBonduelle SCA - Société en commandite par actions au capital de 57 102 699,50 eurosRCS DUNKERQUE 447 250 044 Villeneuve d’Ascq, le 17 octobre 2025 Communiqué de mise à disposition du document d’enregistrement universel 2024-2025 Le Groupe Bonduelle annonce que son document d’enregistrement universel 2024-2025 a été déposé auprès de l’Autorité des marchés financiers (AMF), le 16 octobre 2025. Ce document est tenu à la disposition du public d...

Bonduelle: 1 director

A director at Bonduelle bought 33,036 shares at 8.975EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri

ODDO : Mémoire : Et si nous étions à l’aube d’un ‘supercycle’ ?

Les prix de la mémoire ont progressé de 15% sur un mois et de ~30% YTD. Cela reflète une forte tension sur l’offre alors que la demande IA est plus élevée qu’attendu. Les stocks de mémoires sont, par ailleurs, au plus bas, ouvrant la voie en 2026 à un supercycle, tiré par l’IA mais aussi par l’intégration de l’Edge AI dans les smartphones/PC. Un marché des semis à ~+15/20% en 2026 est crédible dans ce contexte. Dans notre couverture, cela devrait d’abord bénéficier à ASML, VAT, Siltronic, ASMi e...

Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri

ODDO : Memory: What if we were on the eve of a super cycle?

Memory prices have risen by 15% m-o-m and by ~30% since the start of 2025. This reflects a tight supply situation, with demand for AI stronger than expected. Memory inventories are also at an all-time low, paving the way for a super cycle in 2026, driven by AI but also by the integration of Edge AI in smartphones/PCs. A semis market at ~+15-20% in 2026 is a credible scenario in this context. In our coverage, this should first benefit ASML, VAT, Siltronic, ASMi and SUSS (Outperform vs Neutral), f...

 PRESS RELEASE

BONDUELLE - Monthly statement of the number of shares and voting right...

BONDUELLE - Monthly statement of the number of shares and voting rights BONDUELLE  Head office: "La Woestyne" - 59173 Renescure - FranceBonduelle a French S.C.A (Partnership limited by Shares) with a capital of 57 102 699,50 eurosRegistered under number: 447 250 044 (Dunkerque Commercial and Companies Register) MONTHLY INFORMATION REGARDING THE TOTAL NUMBER OF VOTING RIGHTS  AND SHARES FORMING THE COMPANY’S SHARE CAPITAL ARTICLE 223-16 OF THE GENERAL REGULATION OF THE FINANCIAL MARKET AUTHORITY Date of the latest informationTotal number of shares forming capitalNumber of voting rights30....

 PRESS RELEASE

BONDUELLE - Déclaration mensuelle du nombre d'actions et de droits de ...

BONDUELLE - Déclaration mensuelle du nombre d'actions et de droits de vote BONDUELLE  Siège social - "La Woestyne" - 59173 Renescure - FranceBonduelle SCA - Société en commandite par actions au capital de 57 102 699,50 eurosRCS DUNKERQUE 447 250 044 INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DES DROITS DE VOTE  ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL ARTICLE 223-16 DU REGLEMENT GENERAL DE L’AUTORITE DES MARCHES FINANCIERS Date d’arrêté des informationsNombre total d’actions composant le capital Nombre total de droits de vote30.09.202532 630 114Total théorique 52 507 209 Total réel* ...

Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
 PRESS RELEASE

DBV Technologies Announces Sale of approximately $30 million of ADSs T...

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq Châtillon, France, October 6, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company’s At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares ...

 PRESS RELEASE

DBV Technologies annonce un placement d’ADS pour un montant d’environ ...

DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq Châtillon, France, 6 octobre 2025 DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (la « Société » ou « DBV ») (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Capital Market : DBVT), société biopharmaceutique en phase clinique, annonce ce jour, dans le cadre de son programme de financement dit « At-The-Ma...

 PRESS RELEASE

Valneva Strengthens Financial Position by Refinancing Debt with Pharma...

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates New debt facility extends repayment from Q1 2026 to Q4 2030, lowers interest rate and provides access to additional capital for future business developmentCompany adjusts 2025 financial guidance and provides key business updates Saint-Herblain (France), October 6, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has entered into a debt facility for up to $500 million in non-dilutive financing with funds managed by Pharma...

 PRESS RELEASE

Valneva consolide sa position de trésorerie en refinançant sa dette au...

Valneva consolide sa position de trésorerie en refinançant sa dette auprès de Pharmakon Advisors et fait un point sur ses activités Le nouvel accord de prêt diffère le remboursement de la dette du premier trimestre 2026 au quatrième trimestre 2030, à un taux d’intérêt inférieur au précédent, et offre la possibilité d’obtenir davantage de financement pour des activités de Business DevelopmentLa Société ajuste ses perspectives financières pour 2025 et fait un point sur ses activités Saint-Herblain (France), le 6 octobre 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialis...

 PRESS RELEASE

VALNEVA Declaration of shares and voting rights: September 30, 2025

VALNEVA Declaration of shares and voting rights: September 30, 2025 VALNEVA Declaration of shares and voting rights September 30, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: October 6, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal n...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch